Home » Clinical Trials » Leukemia » NCT04030195
NCT04030195

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Study Summary

This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.

Want to learn more about this trial?

Request More Info

Interventions

PBCAR20AGENETIC
Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic "3+3" dose escalation will be applied.
FludarabineDRUG
Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
CyclophosphamideDRUG
Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).

Study Locations

FacilityCityStateCountry
City of HopeDuarteCaliforniaUnited States
Stanford UniversityStanfordCaliforniaUnited States
Columbia UniversityNew YorkNew YorkUnited States
Cleveland ClinicClevelandOhioUnited States
MD Anderson Cancer CenterHoustonTexasUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026